Phase 2b study of the safety, efficacy and pharmacokinetics of telaprevir in combination with peginterferon alpha 2a + ribavirin in liver transplant patients with recurrent hepatitis C genotype 1 (REFRESH)

Trial Profile

Phase 2b study of the safety, efficacy and pharmacokinetics of telaprevir in combination with peginterferon alpha 2a + ribavirin in liver transplant patients with recurrent hepatitis C genotype 1 (REFRESH)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2013

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REFRESH
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 16 May 2013 Interim data, from the first 23 patients, presented at the American Transplant Congress - 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
    • 16 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top